Global Benign Prostatic Hyperplasia (BPH) Drugs Market Data Survey Report 2013-2025
Table of Contents
1 Global Market Overview
- 1.1 Scope of Statistics
- 1.1.1 Scope of Products
- 1.1.2 Scope of Manufacturers
- 1.1.3 Scope of Application
- 1.1.4 Scope of Type
- 1.1.5 Scope of Regions/Countries
- 1.2 Global Market Size
2 Regional Market
- 2.1 Regional Production
- 2.2 Regional Demand
- 2.3 Regional Trade
3 Key Manufacturers
- 3.1 Astellas Pharma
- 3.1.1 Company Information
- 3.1.2 Product & Services
- 3.1.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
- 3.1.4 Recent Development
- 3.2 Eli Lilly
- 3.2.1 Company Information
- 3.2.2 Product & Services
- 3.2.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
- 3.2.4 Recent Development
- 3.3 GlaxoSmithKline
- 3.3.1 Company Information
- 3.3.2 Product & Services
- 3.3.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
- 3.3.4 Recent Development
- 3.4 Sanofi
- 3.4.1 Company Information
- 3.4.2 Product & Services
- 3.4.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
- 3.4.4 Recent Development
- 3.5 ADC Therapeutics
- 3.5.1 Company Information
- 3.5.2 Product & Services
- 3.5.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
- 3.5.4 Recent Development
- 3.6 Bayer HealthCare
- 3.6.1 Company Information
- 3.6.2 Product & Services
- 3.6.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
- 3.6.4 Recent Development
- 3.7 Bristol-Myers Squibb
- 3.7.1 Company Information
- 3.7.2 Product & Services
- 3.7.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
- 3.7.4 Recent Development
- 3.8 Valeant Pharmaceuticals
- 3.8.1 Company Information
- 3.8.2 Product & Services
- 3.8.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
- 3.8.4 Recent Development
- 3.9 Endo Pharmaceuticals
- 3.9.1 Company Information
- 3.9.2 Product & Services
- 3.9.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
- 3.9.4 Recent Development
- 3.10 Foresee Pharmaceuticals
- 3.10.1 Company Information
- 3.10.2 Product & Services
- 3.10.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
- 3.10.4 Recent Development
- 3.11 Madrigal Pharmaceuticals
- 3.11.1 Company Information
- 3.11.2 Product & Services
- 3.11.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
- 3.11.4 Recent Development
- 3.12 Merck
- 3.12.1 Company Information
- 3.12.2 Product & Services
- 3.12.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
- 3.12.4 Recent Development
- 3.13 Novartis
- 3.13.1 Company Information
- 3.13.2 Product & Services
- 3.13.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
- 3.13.4 Recent Development
- 3.14 Spectrum Pharmaceuticals
- 3.14.1 Company Information
- 3.14.2 Product & Services
- 3.14.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
- 3.14.4 Recent Development
- 3.15 Takeda Pharmaceuticals
- 3.15.1 Company Information
- 3.15.2 Product & Services
- 3.15.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
- 3.15.4 Recent Development
- 3.16 Teva
- 3.16.1 Company Information
- 3.16.2 Product & Services
- 3.16.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
- 3.16.4 Recent Development
- 3.17 Advaxis
- 3.17.1 Company Information
- 3.17.2 Product & Services
- 3.17.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
- 3.17.4 Recent Development
- 3.18 ANI Pharmaceuticals
- 3.18.1 Company Information
- 3.18.2 Product & Services
- 3.18.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
- 3.19 BHR Pharma
- 3.19.1 Company Information
- 3.19.2 Product & Services
- 3.19.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
4 Major Application
- 4.1 Hospitals
- 4.1.1 Overview
- 4.1.2 Hospitals Market Size and Forecast
- 4.2 Clinics
- 4.2.1 Overview
- 4.2.2 Clinics Market Size and Forecast
- 4.3 Others
- 4.3.1 Overview
- 4.3.2 Others Market Size and Forecast
5 Market by Type
5.By Alpha-blocker
- 5.1 Alpha-blocker
- 5.1.1 Overview
- 5.1.2 Alpha-blocker Market Size and Forecast
- 5.2 Phosphodiesterase Type-5 Inhibitors
- 5.2.1 Overview
- 5.2.2 Phosphodiesterase Type-5 Inhibitors Market Size and Forecast
- 5.3 5-alpha-Reductase Inhibitors
- 5.3.1 Overview
- 5.3.2 5-alpha-Reductase Inhibitors Market Size and Forecast
6 Price Overview
- 6.1 Price by Manufacturers
- 6.2 Price by Application
- 6.3 Price by Type
7 Conclusion
Summary
The global Benign Prostatic Hyperplasia (BPH) Drugs market will reach xxx Million USD in 2019 with CAGR xx% 2019-2025. The main contents of the report including:
Global market size and forecast
Regional market size, production data and export & import
Key manufacturers profile, products & services, sales data of business
Global market size by Major Application
Global market size by Major Type
Key manufacturers are included based on company profile, sales data and product specifications etc.:
Astellas Pharma
Eli Lilly
GlaxoSmithKline
Sanofi
ADC Therapeutics
Bayer HealthCare
Bristol-Myers Squibb
Valeant Pharmaceuticals
Endo Pharmaceuticals
Foresee Pharmaceuticals
Madrigal Pharmaceuticals
Merck
Novartis
Spectrum Pharmaceuticals
Takeda Pharmaceuticals
Teva
Advaxis
ANI Pharmaceuticals
BHR Pharma
Major applications as follows:
Hospitals
Clinics
Others
Major Type as follows:
Alpha-blocker
Phosphodiesterase Type-5 Inhibitors
5-alpha-Reductase Inhibitors
Regional market size, production data and export & import:
Asia-Pacific
North America
Europe
South America
Middle East & Africa